A standard autologous hematopoietic stem cell transplant (AHSCT) safely and effectively prolongs survival and delays cancer progression in adults with multiple myeloma, a…
Myeloma
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Latest news
The subcutaneous (under-the-skin) formulation of Darzalex (daratumumab) has been approved in the European Union as part of a combination treatment for adults with newly…
Johnson & Johnson (J&J) is asking regulatory authorities in the European Union to approve a combination treatment based on the subcutaneous, or under-the-skin, formulation…
Real-world treatment with the cell therapy Carvykti (ciltacabtagene autoleucel) was found to be highly effective among people with difficult-to-treat multiple myeloma in a multicenter…
Johnson & Johnson (J&J) is seeking U.S. Food and Drug Administration (FDA) approval for a quadruple treatment regimen based on Darzalex Faspro (daratumumab…
A single infusion of the cell therapy Carvykti (ciltacabtagene autoleucel) reduced the risk of death by 45% relative to standard treatment regimens for multiple…
